Evidence map›Paper›PMID 42157275›Full record

ArticleOrphanet journal of rare diseases2026

The genetic and clinical characteristics of oculopharyngeal muscular dystrophy patients in Israel.

Merav Ben-David, Lior Greenbaum, Vera Nikitn, Alex Zvulunov, Hagit Charas, Naama Divon, Tali Barkan, Odelia Chorin, Haike Reznik-Wolf, Ofira Zloto and 3 more

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Merav Ben-David *Department of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Lior Greenbaum *The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Vera NikitnDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Alex ZvulunovDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Hagit CharasDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Naama DivonDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Tali BarkanThe Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Odelia ChorinThe Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Haike Reznik-WolfThe Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Ofira ZlotoMultidisciplinary Service for OPMD Patients, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Limor BenyaminiMultidisciplinary Service for OPMD Patients, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel.
Shahar ShellyDepartment of Neurology, Rambam Medical Center, Haifa, Israel.
Amir DoriDepartment of Neurology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. amirdori@tauex.tau.ac.il.ORCID http://orcid.org/0000-0003-4633-1481

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant myopathy, caused by a (GCN)n/polyalanine repeat expansion in the PABPN1 gene. In Israel, OPMD is particularly prevalent among individuals of Jewish Bukharian descent due to a (GCN)13 repeat expansion. In this retrospective study, we collected genetic and clinical data of OPMD patients who visited the Israeli reference clinic from its opening in 2022 through September 2025 and were enrolled in the Israeli OPMD registry (IsrO-PMD).

resultsA total of 102 Jewish individuals with OPMD symptoms and a confirmed molecular diagnosis were identified (52 males, 51.0%). The heterozygous (GCN)13 repeat allele (10/13 genotype) was found in 95 patients (93.1%), of whom 89 (93.7%) were of Bukharian descent, five (5.6%) were of Bulgarian origin, and a single patient was from Georgia. In this 10/13 genotype group (n = 95), initial symptoms were dysphagia and ptosis, which occurred at a similar mean age of 53.0 ± 8.3 and 53.9 ± 7.2 years, respectively. Symptoms of limb muscle weakness occurred significantly later, at a mean age of 57.9 ± 10.2 years. Overall, the onset of symptoms occurred approximately 4 years earlier in females (48.9 ± 7.9, n = 48) than in males (52.6 ± 7.1, n = 47), and this difference was statistically significant (p = 0.02). However, the difference did not reach significance when calculated for each of the three symptoms separately. On evaluation, at a mean age of 61.6 ± 10.7 years, dysphagia was present in 92/95 (96.8%) of patients, ptosis in 85/95 (89.5%), and limb muscle weakness in 56/95 (58.9%) of cases, most notably of hip flexion and abduction. Different genotypes were detected in seven patients: Three of Bukharian descent were homozygous for (GCN)13 repeats, three of Karaite descent were homozygous for (GCN)11 repeats, and one of Tunisian origion was heterozygous for (GCN)15 repeats (10/15 genotype). DISCUSSION: While most OPMD patients in Israel are of Jewish Bukharian descent, patients from other origins were also identified. Dysphagia and ptosis are the common initial symptoms, and overall, the onset of symptoms was reportedly earlier in females. Proximal muscle weakness becomes common with disease progression. Further studies are required to delineate genotype-phenotype correlations.

Indexed as

Muscular Dystrophy, OculopharyngealAdultAgedFemaleGenotypeHumansIsraelJewsMaleMiddle AgedPoly(A)-Binding Protein IRetrospective StudiesPABPN1 protein, humanPoly(A)-Binding Protein IMyopathyOculopharyngeal muscular dystrophyPABPN1Trinucleotide repeat expansion

Identifiers

PMID42157275
PMCPMC13188457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.